Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Symmetry Surgical, a subsidiary of orthopedic implants and instruments maker Symmetry Medical ( SMA - Analyst Report ) , recently entered into a distribution agreement with Canada-based AMT Electrosurgery Inc. (“AMT”). Per the deal, AMT will be the sole distributor of Symmetry Surgical’s entire portfolio of medical devices in Canada.
The distribution agreement is in line with Symmetry Surgical’s focus on worldwide expansion of its business inclusive of all brands under the erstwhile Codman Surgical Instruments and SSi. AMT supplies specialized surgical systems to more than 400 hospitals in Canada. Given AMT’s strong presence in the Canadian market, this partnership should further expand Symmetry’s foothold in the global market.
Earlier, in June, Symmetry Surgical had completed a distribution agreement with Japan Surgical Specialty (‘JSS’) Corporation to sell its products in the Japanese market. The company had also completed a distribution agreement to directly distribute its offerings in Australia and New Zealand.
Symmetry Medical is the largest OEM provider of implants and related surgical instruments and cases to orthopedic devices manufacturers. Its major customers include Johnson & Johnson’s ( JNJ - Analyst Report ) DePuy, Stryker ( SYK - Analyst Report ) and Zimmer Holdings ( ZMH - Analyst Report ) .
The acquisition of the surgical instruments business of Codman and Shurtleff Inc. (Codman), a Johnson & Johnson enterprise, in December 2011 shaped Symmetry Surgical into a business worth $100 million. The Specialty Surgical Instruments (SSi) was acquired in 2007.
However, Symmetry Medical’s core OEM Solutions business is facing declining capital spending, procedural and pricing pressure from the weak global orthopedic market. In addition, the current weakness in the economic environment makes us cautious about the company’s future growth prospects. We believe that the company needs to improve its operational efficiency to overcome these macroeconomic challenges.
We currently have a Neutral recommendation on Symmetry Medical, which carries a short-term Zacks #4 Rank (Sell rating).
Read the full reports :
Analyst Report on SMA
Analyst Report on SYK
Analyst Report on ZMH
Analyst Report on JNJ